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Summary 
We have demonstrated spontaneous nitric oxide (NO) production by primary synovial cultures 
from rheumatoid (RA) and osteoarthritis patients. Increased NO production followed addition 
of staphylococcal enterotoxin B.  Immunochemical double staining with specific anti-human 
inducible NO synthase (iNOS) and nonspecific esterase (NSE), or anti-CD68 (markers for tis- 
sue  macrophages)  showed  that  although  many lining layer cells  in  RA  synovium expressed 
iNOS, most ('-'90%) were NSE- and CD68-, with only a minor population (~10%) which 
were iNOS +, CD68+/NSE §  These data demonstrate the capacity for high output of NO by 
human synovial tissue  and show that, although human macrophages can express high levels of 
iNOS, the majority of cells expressing iNOS are fibroblasts.  We also report that synoviocytes, 
and macrophage cell lines, cultured with the NO donor, S-nitroso-acetyl penicillamine, pro- 
duced high concentrations of tumor necrosis factor (TNF)-oe. These results  suggest that NO 
may mediate pathology in P,A through the induction of TNF-ot production. 
R 
heumatoid arthritis  (RA)  is characterized by chronic 
inflammatory infiltration of the synovium, with de- 
struction of cartilage and underlying bone, mediated by cy- 
tokines, metalloproteinases and superoxide radicals  (1). Ni- 
tric Oxide is produced constitutively by endothelial (eNOS) 
or neuronal NO synthases,  or in higher concentrations by 
inducible NO synthase (iNOS) after stimulation by bacte- 
rial products and cytokines, including IFN-',/, TNF-ci, and 
IL-1 (2, 3). As such, it has emerged as an important regula- 
tory and effector mediator in several models of inflamma- 
tion (3),  including streptococcal cell wall and adjuvant ar- 
thritis in the rat (4,  5) and renal and articular pathology in 
MRL-Ipr/lpr  mice (6,  7). iNOS activity has been demon- 
strated in rodent synoviocytes and macrophages, and in ro- 
dent and human neutrophils,  chondrocytes and mast  cells 
(2,  8-10).  Evidence  for NO  production  in  human  syn- 
ovium is provided by elevation of nitrite levels in synovial 
fluid relative to serum in I:I.A patients (11) and by demon- 
stration of elevated urinary nitrate/creatinine ratios in RA 
(12).  Furthermore, a recent report has suggested the pres- 
ence of iNOS in human synovium and implied that mac- 
rophages are the major source ofsynovial NO (13). 
We  now provide direct evidence for spontaneous  NO 
production by human synovial tissue from RA and osteoar- 
thritis (OA) patients, which may be further upregulated by 
bacterial superantigen. We have shown that the predomi- 
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nant cellular source of NO is the synovial fibroblast. Fur- 
thermore, NO activated synovial cells produced TNF-oL, a 
critical proinflammatory cytokine in RA synovitis (1). 
Materials  and  Methods 
Patients~Cell Culture.  Synovial tissue was obtained at arthro- 
plasty from 25 patients satisfying American College  of Rheuma- 
tology criteria for RA (14), and 7 with clinical and radiological 
features of OA (mean age 62, range 28-83 yr). Single-cell suspen- 
sions were prepared from 13 RA and 7 OA tissues as previously 
described (15). Cell subsets assessed by FACS  |  analysis fell within 
ranges previously reported  (15). 106  cells/ml  were  cultured  in 
triplicate in complete Dulbecco's MEM,  10% FCS (GIBCO BRL, 
Paisley, UK) for 72 h unless indicated. LPS, stephylococcal  entero- 
toxin B (SEB) (Sigma Chemical Co., Poole, UK), NC'-monome  - 
thyl-g-arginine  (L-NMMA)  (provided by Dr. H. Hodson, Well- 
come, Beckenham, UK). L-NMMA did not reduce cell viability or 
proliferation by synovial cultures to SEB (data not shown). 
NO Measurement.  NO production was measured as its oxida- 
tive product,  nitrite,  using the Griess reaction  as described  (7). 
Sensitivity was 2 p.M. 
Immunohistochemistry.  Acetone fixed frozen sections (3-6 p.m) 
from 10 RA synovia, blocked with goat/human serum, were in- 
cubated  with  rabbit  antiserum  against a  human  iNOS  peptide 
(NO53),  (16) then with biotin goat anti-rabbit  Ig (DAKO, High 
Wycombe, UK), streptavidin-alkaline phosphatase (DAKO), fast 
red  (Vector, Peterborough,  UK) and hemotoxylin for light mi- 
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Cultures 
Drug 
Patients  Duration  Therapy  Unstimulated  SEB* 
RA  yr 
RA1  14 
RA2  20 
RA3  5 
RA4  13 
RA5  9 
RA6  19 
RA7  22 
RA8  20 
RA9  15 
RA10  20 
RAll  10 
RA12  10 
RAI3  15 
OA 
OA1  10 
OA2  7 
OA3  5 
OA4  10 
OA5  3 
OA6  5 
OA7  8 
Nitrite IzM 
H  9.3  (3.0)  33  (7)* 
M  13  (1.7)  34  (0.5) 
M+  H  +  P  51  (2.7)  131  (6) 
G  <2  6  (2.2) 
M  10.5  (1.3)  16.2  (0.5) 
A  +  P  <2  11.7  (3.2)~: 
S +  e  10.1  (0.3)  32  (5.9) 
--  <2  <2 
D  10.4  (2)  8.8  (t .0)r 
--  5.2  (1.2)  6.7  (2.8)* 
--  3.2  (0.5)  44  (8) 
m  4.3  (0.5)  41  (3.9) 
--  <2  19  (2.5) 
15  (0.5)  32  (3.6) 
<2  3.3  (1.0)* 
<2  3.2  (1.0)* 
22  (2.5)  57  (8) 
128  (26)  98  (8) 
10  (3.3)  24  (3) 
76  (9)  112  (8) 
SEB-stimulated  RA  synovial  tissues produce  enhanced nitrite levels 
(mean +  SD, P <0.01). 
*Optimal response to SEB (range 1-10 b~g/ml) at 72 h for each patient. 
* 1 Ixg/ml LPS present. G, IM gold; S, sulphasalazine; M, methotrexate; 
H,  hydroxychloroquine;  D,  penicillamine;  A,  azathioprine;  and  P, 
prednisolone. 
croscopy.  For double immunofluorescence, murine anti-CD3 or 
anti-CD68  was  followed  by  FITC  Fab2 goat  anti-mouse  Ig 
(DAKO), and anti-iNOS antiserum by biotin goat anti-rabbit Ig 
and PE-streptavidin (DAKO). Positive staining was  acquired by 
confocal  microscopy  (Nikon  Optiphot-2;  Bio-Rad,  Hertford- 
shire,  UK).  Normal  rabbit  serum  (NRS)  or  murine  IgG1 
(DAKO) of irrelevant specificity served as controls and were neg- 
ative even after  coincubation with anti-CD68 or NRS,  respec- 
tively (data not shown).  For neutralization experiments, the im- 
nmnizing  iNOS  peptide  YRASLEMSAL,  rat  iNOS  peptide 
YEEPKATRL (COOH temfinus rat iNOS), or recombinant hu- 
man eNOS  (gift of Dr. I. Charles, The Cruciform Project, Uni- 
versity College London, UK) at 50 txg/ml were incubated over- 
night at 4~  with anti-iNOS before staining. Nonspecific esterase 
(NSE)  was  detected  as  described  (17)  on  sections stained with 
anti-iNOS  developed  with  fast  blue  (Vector)  to  contrast  with 
NSE.  Staining was  assessed  by two  histologists counting >500 
cells  in more  than three  high power  fields per section  (￿ 
The  percentage  of iNOS  positive  cells  is  expressed  as  (positive 
cells)/(total number cells in field)  ￿  100. 
RT-PCR.  RT-PCR was performed as previously described (8). 
Primers for human iNOS were  a  gift from Dr.  I.  Charles:  -5'- 
GCCTCGCTCTGGAAAG-3'  and  5'-TCCATGCAGCAA- 
CCTT-3'. Human chondrocyte iNOS cDNA and [3-actin primers 
5'-CCACACTGTGCCCATCTACGAGGGGT-3' and 5'-AGG- 
GCAGTGATCTCCTTCTGCATCCT-3' (Genosys, Cambridge, 
UK)  served  as  internal  controls.  The  PCR  product  was  se- 
quenced  (Amersham  Life  Science,  Buckinghamshire,  UK)  and 
was identical to that predicted from human chondrocyte iNOS (8). 
Induction qfl TNF-a Syn&esis by NO.  Synoviocyte/macrophage 
cultures were prepared using adherent cells  after  16 h  culture of 
primary synovial tissue digests,  or synovial fluid mononuclear cells 
obtained using lymphoprep (Nycomed Pharma,  Oslo,  Norway). 
U937  cells  were  matured for  24  h  with  10  nM PMA  (Sigma). 
Cells at 2  ￿  10"/ml were stimulated with S-nitroso-acetyl peni- 
cillamine (SNAP) or N-acetyl penicillamine (NAP, gifts from Dr. 
I.  Charles)  for  48  h  and TNF-~x concentrations determined by 
ELISA using paired antibodies (MAbl, MAbl 1,  sensitivity < 10 
pg/ml; PharMingen, San Diego, CA). Cell viability was >9(i)% by 
trypan blue exclusion. U937 cells cultured with  1 n~Vl SNAP for 
48 h, then pulsed with 1 ~Ci [3H]thymidine for 6 h, show similar 
uptake to controls (data not shown). 
Statistical Analysis.  Comparison between groups was by Mann- 
Whitney test.  Paired  samples  were  compared  using a  t  test  or 
Wilcoxon matched pairs signed rank sum test. 
Results  and  Discussion 
Nitrite production by primary synovial cultures from 9/ 
13  RA  patients  and  5/70A  patients was  detected  in the 
absence of exogenous stimulation (Table 1). Together with 
the demonstration of iNOS  mRNA  expression in synovial 
tissue (Fig.  1), these observations show that NO  generation 
has been initiated in vivo in both RA  and OA  synovium. 
No  difference  was  observed  between  nitrite produced  by 
synovial cultures from RA  and OA  tissues, nor was serum 
acute phase response correlated with nitrite levels (data not 
shown). The superantigen SEB induces T  cell proliferation, 
cytokine  secretion,  and  upregulates  mononuclear cell  cy- 
tokine  expression  after  MHC  class  II  binding  (18,  19). 
Addition of SEB to synovial cultures from RA and OA pa- 
tients  clearly  induced  increased  NO  synthesis  in  a  dose- 
Figure  1.  RT-PCR  for  human iNOS  mRNA in snap-frozen  syn- 
ovium. Lanes 1-4, representative RA patients; lane 5, representative OA 
patient; lane 6, human iNOS cDNA; lane 7, negative control. 
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Figure 2.  (a) SEB-induced  nitrite production by synovial cultures from 
representative patients R.A12 (open)  and OA06 (dosed).  I-1 SEB 1 txg/ml; 
O, SEB (1 p,g/ml) + LPS (1 l~g/ml). (b) Nitrite production by RA syn- 
ovial tissue over time (representing four similar experiments). Supema- 
and time-dependent  manner  (Fig.  2,  Table  1).  When LPS 
(0.1-10  ~g/ml)  was  added  with  SEB,  no  significant  in- 
crease in nitrite concentration was observed. Production of 
nitrite  was inhibited  by addition  of L-NMMA  (1  raM),  a 
competitive iNOS inhibitor (Fig. 2  b). Thus, in addition to 
cartilage  (20), human synovial membrane itself has the po- 
tential for significant NO generation. 
Previous  efforts  to  localize  iNOS  in  human  synovium 
used  cross-reacting  antibodies  to  rodent  iNOS  (13).  We 
used  rabbit  antiserum  raised  specifically  against  a  peptide 
from human iNOS  (17), which recognized neither human 
eNOS nor rodent iNOS. Intracytoplasmic staining (Fig. 3 a) 
was observed in 10 RA synovia in the following distribution 
(mean +  SD [range]): lining layer 19 +  13.1  [2-56], inter- 
stitium 5  +  5.6  [0--20], aggregates 7  +  7.8  [0-37] (P <0.001 
LL vs Is or Agg). Variable iNOS staining between patients 
reflected the  heterogeneity of spontaneous  nitrite  produc- 
tion in primary culture,  iNOS + smooth muscle and endo- 
thelial  cells  were  identified  around  blood  vessels  in  8/10 
RA  tissues.  Staining was  abohshed by preincubation  with 
human iNOS peptide  (Fig. 3  b), but not with either rodent 
iNOS  peptide  or  recombinant  human  eNOS  (Fig.  3  c), 
demonstrating specificity for human iNOS. 
The RA synovial lining layer consists primarily  of acti- 
vated macrophages and fibroblasts (1).  Double staining with 
NSE and anti-iNOS  (Fig. 3 d) revealed that the majority of 
iNOS + cells  (89  --- 5%)  in the hning layer,  or interstitium, 
were NSE- and therefore unlikely to be macrophages (Ta- 
tants were harvested at times indicated and kept for simultaneous assay. 
[~, SEB (1 p.g/ml); ￿9  SEB (1 la.g/ml) +  LPS (1 ~g/ml); staphylococcal 
exterotoxin, SEB (1 I~g/ml) + L-NMMA (1 raM); A, LPS (1 t~g/ml). 
Figure 3.  RA synovial lining layer stained with (a) anti-human iNOS antiserum (fast red), preincubated with (b) human iNOS peptide, or (c) anti- 
rodent iNOS peptide. Preincubation with human eNOS was similar to (c). (d) Double stain with anti-human iNOS (fast blue) and NSE (red-brown): ar- 
row shows a double-labeled cell (￿ 
1521  Mclnnes et al.  Brief Definitive Report Figure 4.  Confocal images ofP,.A synovial sections double-stained  with anti-human iNOS (red) and (a) anti-CD68 (green), showing that nmst iNOS- 
positive  ceils are CD68-  (￿  (b) anti-CD68 at higher magnification,  showing  that  CD68+/iNOS  + cells are present  (double stain appears yellow 
[￿  or (c) anti-CD3 (green), showing that T ceils are iNOS- (￿ 
ble  2).  Confocal  microscopy  also  demonstrated  that  most  a 
250  - 
iNOS +  cells  were  CD68-  (Fig.  4  a),  although  iNOS+/ 
CD68 +  cells were  occasionally  observed  (Fig.  4  b).  Thus,  200- 
although  synovial  macrophages  possess  the  capability  of 
NO  generation,  fibroblastlike  synoviocytes  are  the  pre- 
dominant  source  of NO  in  vivo.  Moreover,  a  majority  of  ~  ~5o- 
NSE +  and  CD68 +  cells  in  the  lining  layer  were  iNOS  ,  ~  100- 
indicating that  most macrophages  are not directly involved 
in  NO  production  (Table  2).  CD3 +  synovial T  cells were  s0- 
all iNOS-  (Fig. 4  c). The shared species and isotype ofanti- 
CD3  with  anti-CD68  antibody  provided  an  additional  0 
specificity  control  for  the  double  staining  observed  with 
anti-iNOS and anti-CD68. 
There  is  currently  controversy as  to  the  capacity  of hu- 
man  macrophages  to produce  NO  (21,  22).  Optimal  con- 
ditions  for  iNOS  expression  in  murine  macrophages  are 
apparently  distinct from those required in the human,  per-  b 
haps  reflecting the  tissue  of origin,  since blood  monocytes  8oo 
are  mainly  used  in  human  experiments.  Where  NO  pro- 
duction by human  macrophages  was  detectable  (22),  levels 
Table  2.  Colocalization qf iNOS with NSE in RA Synovium 
NSE +/iNOS-  NSE-/iNOS +  NSE +/iNOS  + 
Percent  positive cells 
49  +  24  45  +  23  5  +- 3.1 
(0-80)  (16-93)  (0-12.5) 
1LA sections  (n  =  4) were double stained  with anti-human iNOS and 
NSE. Greater than 250 lining layer and interstitial  area cells positive  for 
NSE and/or iNOS were counted per section  and the number of single 
or double positive cells expressed as a percentage of the total number of 
stained cells counted (mean  4- SD [range]). 
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Figure 5.  TNF-c~ production  (mean 4- SEM) in response to SNAP by 
(a) adherent  cells from RA synovial fluid (SFAC) (O, n =  4), or P,A syn- 
ovial tissue (U], n =  2); or (b) PMA-matured U937 cells (•,  SNAP; A, 
NAP: representative  of three  mnilar  experiments).  NAP did not induce 
TNF-a production  from  SFAC (n  =  3, data not shown).  2 mM SNAP 
contained  <0.00If  IU LPS by limulus antebocyte  lysate assay (E-toxate; 
Sigma). 
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macrophages. Our study demonstrates clearly that some syn- 
ovial macrophages in RA can express high levels of iNOS. 
The reason why only a limited  number of macrophages is 
activated to produce NO is at present unclear. 
We next investigated a potential role for NO in the syn- 
ovial membrane.  U937 cells or synovial mononuclear cells 
cultured with the NO donor, SNAP, produced TNFo~ in a 
dose-dependent manner (Fig. 5). RA synovial macrophages 
are activated, producing proinflammatory cytokines such as 
IL-1,  TNF-o~  (1),  and  IL-15  (23)  and  clinical  trials  using 
monoclonal anti-TNF-0~  therapy  indicate  that  such  cyto- 
kine generation is critical in ongoing synovitis (24).  How- 
ever,  factors  responsible  for  TNF-o~  upregulation  remain 
unclear.  Our data  clearly show that synovial macrophages 
may  express  iNOS,  but  are  unlikely  to  be  the  principle 
producers of NO. A  reciprocal pathway may exist whereby 
NO  from  synovial  fibroblasts  enhances  proinflammatory 
cytokine production by macrophages,  which in turn  may 
upregulate  iNOS  expression  (2,  3),  thereby  generating  a 
positive  feedback  loop.  NO  also  upregulates  MMP  pro- 
duction (25)  and is implicated in IL-113 mediated inhibition 
of proteoglycan synthesis  (26),  suggesting a  proinflamma- 
tory role for NO. However, NO levels in our synovial cul- 
tures are sufficient to suppress T  cell proliferation and may 
contribute  to  the  hyporesponsiveness  of synovial  T  lym- 
phocytes (27). In addition, an acute chondroprotective role 
for endogenous NO  in bovine cartilage  has recently been 
proposed (28).  Thus,  in contrast to the situation in animal 
models in which NO  is usually detrimental  (4,  5),  the  net 
effect  of NO  production  in  human  arthritis  remains  un- 
clear. 
Both  RA  and  OA  synovia  produced  NO.  Although 
some  OA  synovial  tissue  contains  an  inflammatory  infil- 
trate, the etiology of OA is not considered to be inflamma- 
tory.  NO  production is therefore  unlikely to be a  unique 
feature of primary inflammatory arthritides,  but may reflect 
a  nonspecific  synovial response  to injury  or inflammation 
with potential protective or pathologic consequences. 
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